PMID- 16583740
OWN - NLM
STAT- MEDLINE
DCOM- 20060509
LR  - 20191109
IS  - 0911-4300 (Print)
IS  - 0911-4300 (Linking)
VI  - 25
IP  - 4
DP  - 2002 Aug
TI  - [Intravenous immunoglobulin replacement therapy in X-linked agammaglobulinemia].
PG  - 337-43
AB  - Intravenous immunoglobulin (IVIG) replacement therapy is the mainstay of therapy 
      for X linked agammaglobulinemia (XLA). This study was attempted to investigate 
      how patients with XLA were treated with IVIG in Japan. Data were complied from 
      questionnaires filled in by the physicians. One hundred eighteen medical records 
      had been given from 134 patients. One hundred eleven patients had been treated 
      with IVIG. Most patients had been administered IVIG every 2 to 4 weeks, and 
      maintained serum IgG trough levels of 400 mg/dl. Some of patients had adverse 
      effects of IVIG. Antibiotics, especially macrolides, had been administered in 
      some of patients. A few patients, despite the maintenance of higher trough 
      levels, were associated with infections. The present study suggests that IVIG 
      should be administered dependent on personal infection histories.
FAU - Kanegane, Hirokazu
AU  - Kanegane H
AD  - Department of Pediatrics, Faculty of Medicine, Toyama Medical and Pharmaceutical 
      University, 2630, Toyama Sugitani 930-0194, Japan.
FAU - Nomura, Keiko
AU  - Nomura K
FAU - Futatani, Takeshi
AU  - Futatani T
FAU - Miyawaki, Toshio
AU  - Miyawaki T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho Meneki Gakkai Kaishi
JT  - Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology
JID - 9505992
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Macrolides)
SB  - IM
MH  - Agammaglobulinemia/*drug therapy
MH  - Anti-Bacterial Agents/administration & dosage
MH  - Drug Therapy, Combination
MH  - Genetic Diseases, X-Linked/*drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage/adverse effects
MH  - Japan
MH  - Macrolides/administration & dosage
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
RF  - 32
EDAT- 2006/04/06 09:00
MHDA- 2006/05/10 09:00
CRDT- 2006/04/06 09:00
PHST- 2006/04/06 09:00 [pubmed]
PHST- 2006/05/10 09:00 [medline]
PHST- 2006/04/06 09:00 [entrez]
AID - 10.2177/jsci.25.337 [doi]
PST - ppublish
SO  - Nihon Rinsho Meneki Gakkai Kaishi. 2002 Aug;25(4):337-43. doi: 
      10.2177/jsci.25.337.